Glial cells as a target for the development of new therapies for treating Parkinson's disease

Drug News and Perspectives

Volumn 15, Issue 9, 2002, Pages 586-590

  Muramatsu, Yasuko ^a   Araki, Tsutomu ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; PROTEIN S100B;

ALZHEIMER DISEASE; BRADYKINESIA; DEGENERATIVE DISEASE; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; GENE OVEREXPRESSION; GLIA CELL; HUMAN; NERVE CELL; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; RIGIDITY; STRIATONIGRAL DEGENERATION; TARGET CELL; TREMOR;

EID: 0036868976     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.9.740227     Document Type: Review

References (41)

1. Parkinson, J. An Essay on the Shaking Palsy. Sherwood, Neely, and Jones: London, 1817.
2. Agid, Y. Parkinson's disease: Pathophysiology. Lancet 1991, 337: 1321-4.
3. Heikkila, R.E., Hess, A. and Duvoisin, R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 1984, 224: 1451-3.
4. Arai, N., Misugi, K., Goshima, Y. and Misu, Y. Evaluation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model of parkinsonism. Brain Res 1990, 515: 57-63.
5. Muthane, U., Ramsay, K.A., Jiang, H., Lewis, V.J., Donaldson, D., Fernando, S., Ferreira, M. and Przedborski, S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 1994, 126: 195-204.
6. Araki, T., Kumagai, T., Tanaka, K., Matsubara, M., Kato, H., Itoyama, Y. and Imai, Y. Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 2001, 918: 176-81.
7. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.K., Ischiropoulos, H. and Przedborski, S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22: 1763-71.
8. Chiba, K., Trevor, A. and Castagnoli, N., Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120: 574-8.
9. Pifl, C., Giros, B. and Caron, M.G. Dopaminergic transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 1993, 13: 4246-53.
10. Vyas, I., Heikkila, R.E. and Nicklas, W.J. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 1986, 46: 1501-7.
11. Scotcher, K.P., Irwin, I., DeLanney, L.E., Langston, J.W. and Di Monte, D. Effects of 1-methyl-4-phenylpyridium ion on ATP levels of mouse brain synaptosomes. J Neurochem 1990, 54: 1295-301.
12. Gluck, M.R., Krueger, M.J., Ramsay, S.S., Sablin, S.O., Singer, T.P. and Nicklas, W.J. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. J Biol Chem 1994, 269: 3167-74.
13. Ramsay, R.R. and Singer, T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol Chem 1986, 261: 7585-7.
14. Schulz, J.B., Matthews, R.T., Muqit, M.M.K., Browne, S.E. and Beal, M.F. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995, 64: 936-9.
15. Przedborski, S., Lewis, W.J., Yokoyama, R., Shibata, T., Dawson, V.L. and Dawson, T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996, 93: 4565-71.
16. Verkhratsky, A., Orkand, R.K. and Kettenmann, H. Glial calcium: Homeostasis and signaling function. Physiol Rev 1998, 78: 99-141.
17. Barres, B.A. New roles of glia. J Neurosci 1991, 11: 3685-94.
18. Porter, J.T. and McCarthy, K.D. Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol 1997, 51: 439-55.
19. Barres, B.A. Glial ion channels. Curr Opin Neurobiol 1991, 1: 354-9.
20. Coles, J.A. and Abbott, N.J. Signalling from neurons to glial cells in invertebrates. Trends Neurosci 1996, 19: 358-62.
21. Tsacopoulos, M. and Magistretti, P.J. Metabolic coupling between glia and neurons. J Neurosci 1996, 16: 877-85.
22. Newman, E. and Reichenbach, A. The Muller cell: A functional element of the retina. Trends Neurosci 1996, 19: 307-12.
23. Mennerick, S. and Zorumski, C.F. Glial contributions to excitatory neurotransmitter in cultured hippocampal cells. Nature 1994, 368: 59-62.
24. Pfrieger, F.W. and Barres, B.A. Synaptic efficacy enhanced by glial cells in vitro. Science 1997, 277: 1684-7.
25. Nawashiro, H., Brenner, M., Fukui, S., Shimada, K. and Hallenbeck, J.M. High susceptibility to cerebral ischemia in GFAP-null mice. J Cereb Blood Flow Metab 2000, 20: 1040-4.
26. Wang, X.F. and Cynader, M.S. Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem 2000, 74: 1434-42.
27. Dringen, R., Pfeiffer, B. and Hamprecht, B. Synthesis of the antioxidant glutathione in neurons: Supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurochem 1999, 19: 562-9.
28. O'Callaghan, J.P., Miller, D.B. and Reinhard, J.F., Jr. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced damage of striatal dopaminergic fibers attenuates subsequent astrocytes response to MPTP. Neurosci Lett 1990, 117: 228-33.
29. Nakamura, S., Akiguchi, I. and Kimura, J. The histochemical demonstration of MPTP oxidation in postmortem human striatum. Neurosci Lett 1993, 154: 61-4.
30. Muramatsu, Y., Kurosaki, R., Mikami, T., Michimata, M., Matsubara, M., Imai, Y., Kato, H., Itoyama, Y. and Araki, T. Therapeutic effect of neuronal nitric oxidesynthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis 2002, 17: 169-82.
31. Tanji, H., Araki, T., Nagasawa, H. and Itoyama, Y. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP Brain Res 1999, 824: 224-31.
32. Zimmer, D.B., Cornwall, E.H., Landar, A. and Song, W. The S100 protein family: History, function, and expression. Brain Res Bull 1995, 37: 417-29.
33. Van Eldik, I.J., Ehrenfried, B. and Jensen, R.A. Production and characterization of monoclonal antibodies with specificity for the S100 beta polypeptide of brain S100 fractions. Proc Natl Acad Sci USA 1984, 81: 6034-8.
34. Reeves, R.H., Yao, J., Crowley, M.R., Buck, S., Zhang, X., Yarowsky, P., Gearhart, J.D. and Hilt, D.C. Astrocytosis and axonal proliferation in the hippocampus of S100beta transgenic mice. Proc Natl Acad Sci USA 1994, 91: 5359-63.
35. Griffin, W.S.T., Stanley, L.C., Ling, C., White, L.M., White, C.L. and Araoz, C. Brain interteukin-1 and S-100beta immunoreactivity elevated in Down's syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 1989, 86: 7611-5.
36. Sheng, J.G., Mark, R.E. and Griffin, W.S. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol 1997, 94: 1-5.
37. Migheli, A., Cordera, S., Bendotti, C., Atzori, C., Piva, R. and Schiffer, D. S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 1999, 261: 25-8.
38. Selinfreud, R.H., Barger, S.W. and Van Edik, L.J. Neurotrophic S100beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991, 88: 3554-8.
39. Whitaker-Azmitia, P.M., Wingate, M., Borella, A., Gerlai, R., Roder, J. and Azmitia, E.C. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: Implications for Alzheimer's disease and Down's syndrome. Brain Res 1997, 776: 51-60.
40. Matsui, T., Mori, T., Tateishi, N., Kagamiishi, Y., Satoh, S., Katsube, N., Morikawa, E., Morimoto, T., Ikuta, F. and Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: Enhanced astrocytic synthesis of s-100beta in the periinfarct area precedes delayed infarct expansion. J Cereb Blood Flow Metab 2002, 22: 711-22.
41. Tateishi, N., Mori, T., Kagamiishi, Y., Satoh, S., Katsube, N., Morikawa, E., Morimoto, T., Matsui, T. and Asano T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: Suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002, 22: 723-34.